Epigenetic silencing of miR-181b contributes to tumorigenicity in colorectal cancer by targeting RASSF1A

Zhao,Lun-De; Zheng,Wei-Wei; Wang,Gao-Xiang; Kang,Xiao-Chun; Qin,Lei; Ji,Juan-Juan; Hao,Sha

doi:10.3892/ijo.2016.3414

Epigenetic silencing of miR-181b contributes to tumorigenicity in colorectal cancer by targeting RASSF1A

Authors:
- Lun-De Zhao
- Wei-Wei Zheng
- Gao-Xiang Wang
- Xiao-Chun Kang
- Lei Qin
- Juan-Juan Ji
- Sha Hao
View Affiliations

Affiliations: Department of Emergency, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453100, P.R. China, Department of General Surgery, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453100, P.R. China, Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453100, P.R. China, Department of Gastroenterology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453100, P.R. China, Department of Medical Oncology, Jingmen Traditional Chinese Medicine Hospital, Jingmen, Hubei 448000, P.R. China
Published online on: March 3, 2016 https://doi.org/10.3892/ijo.2016.3414
Pages: 1977-1984

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aberrant microRNA expression is common in colorectal cancer and DNA methylation is believed to be responsible for this alteration. In this study, we performed evaluation in vivo and in vitro to determine the role of miR-181b as a potential diagnostic and prognostic biomarker in colorectal cancer. Ninty-seven pairs of colorectal cancer tissues and adjacent normal tissues were collected. The expression level and methylation status of miR-181b was determined in tissue samples and multiple colorectal cancer cell lines. RASSF1A, a predicted target gene of miR-181b, was investigated in vitro. Further mechanistic explorations were conducted. It was found that miR-181b expression was frequently downregulated in cancer samples. This lower expression level resulted from higher hypermethylation in cancer tissue and was closely related to TNM stage. Following artificial synthesis of miR-181b stimulation, colorectal cancer cell proliferation was greatly inhibited in CRC cells while apoptosis percentage markedly increased. miR-181b achieved the tumor suppressive effects via direct targeting of the RASSF1A gene. This study indicated the clinical significance of miR-181b and the influence of miR-181b promoter region in epigenetic silencing of tumorigenicity in colorectal cancer, and implied the possible usage of miR-181b as a diagnostic and prognostic biomarker in colorectal cancer.

View Figures

View References

1	Siegel R, Desantis C and Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117. 2014. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
3	Shah R, Jones E, Vidart V, Kuppen PJ, Conti JA and Francis NK: Biomarkers for early detection of colorectal cancer and polyps: Systematic review. Cancer Epidemiol Biomarkers Prev. 23:1712–1728. 2014. View Article : Google Scholar : PubMed/NCBI
4	Jimenez CR, Knol JC, Meijer GA and Fijneman RJ: Proteomics of colorectal cancer: Overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers. J Proteomics. 73:1873–1895. 2010. View Article : Google Scholar : PubMed/NCBI
5	Xuan Y, Yang H, Zhao L, Lau WB, Lau B, Ren N, Hu Y, Yi T, Zhao X, Zhou S, et al: MicroRNAs in colorectal cancer: Small molecules with big functions. Cancer Lett. 360:89–105. 2015. View Article : Google Scholar
6	Yang X, Zhong J, Ji Y, Li J, Jian Y, Zhang J and Yang W: The expression and clinical significance of microRNAs in colorectal cancer detecting. Tumour Biol. 36:2675–2684. 2015. View Article : Google Scholar
7	Amankwatia EB, Chakravarty P, Carey FA, Weidlich S, Steele RJ, Munro AJ, Wolf CR and Smith G: MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms. Br J Cancer. 112:1480–1490. 2015. View Article : Google Scholar : PubMed/NCBI
8	Taniguchi K, Sugito N, Kumazaki M, Shinohara H, Yamada N, Nakagawa Y, Ito Y, Otsuki Y, Uno B, Uchiyama K, et al: MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer. Cancer Lett. 363:17–27. 2015. View Article : Google Scholar : PubMed/NCBI
9	Wang J, Huang SK, Zhao M, Yang M, Zhong JL, Gu YY, Peng H, Che YQ and Huang CZ: Identification of a circulating microRNA signature for colorectal cancer detection. PLoS One. 9:e874512014. View Article : Google Scholar : PubMed/NCBI
10	Zeng W, Tu Y, Zhu Y, Wang Z, Li C, Lao L and Wu G: Predictive power of circulating miRNAs in detecting colorectal cancer. Tumour Biol. 36:2559–2567. 2015. View Article : Google Scholar
11	Vaish V, Khare T, Verma M and Khare S: Epigenetic therapy for colorectal cancer. Methods Mol Biol. 1238:771–782. 2015. View Article : Google Scholar
12	Dassow H and Aigner A: MicroRNAs (miRNAs) in colorectal cancer: From aberrant expression towards therapy. Curr Pharm Des. 19:1242–1252. 2013.PubMed/NCBI
13	Ma X, Becker Buscaglia LE, Barker JR and Li Y: MicroRNAs in NF-kappaB signaling. J Mol Cell Biol. 3:159–166. 2011. View Article : Google Scholar : PubMed/NCBI
14	Sun YC, Wang J, Guo CC, Sai K, Wang J, Chen FR, Yang QY, Chen YS, Wang J, To TS, et al: MiR-181b sensitizes glioma cells to teniposide by targeting MDM2. BMC Cancer. 14:6112014. View Article : Google Scholar : PubMed/NCBI
15	Bovell LC, Shanmugam C, Putcha BD, Katkoori VR, Zhang B, Bae S, Singh KP, Grizzle WE and Manne U: The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer. Clin Cancer Res. 19:3955–3965. 2013. View Article : Google Scholar : PubMed/NCBI
16	Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML and Struhl K: STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell. 39:493–506. 2010. View Article : Google Scholar : PubMed/NCBI
17	Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, Yamamoto M and Ju J: Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. Cancer Genomics Proteomics. 3:317–324. 2006.
18	Xi Y, Formentini A, Chien M, Weir DB, Russo JJ and Ju J, Kornmann M and Ju J: Prognostic values of microRNAs in colorectal cancer. Biomark Insights. 2:113–121. 2006.
19	Xu R, Ma N, Wang F, Ma L, Chen R, Chen R, Kebinu M, Ma L, Han Z, Ayixiamu, et al: Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer. Onco Targets Ther. 6:925–929. 2013.PubMed/NCBI
20	Watanabe K, Kawahara H, Enomoto H, Toyama Y, Akiba T and Yanaga K: Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer. Anticancer Res. 33:4029–4032. 2013.PubMed/NCBI
21	Jordà M and Peinado MA: Methods for DNA methylation analysis and applications in colon cancer. Mutat Res. 693:84–93. 2010. View Article : Google Scholar : PubMed/NCBI
22	Gyparaki MT, Basdra EK and Papavassiliou AG: DNA methylation biomarkers as diagnostic and prognostic tools in colorectal cancer. J Mol Med Berl. 91:1249–1256. 2013. View Article : Google Scholar : PubMed/NCBI
23	Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, Sugihara K and Mori M: Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol. 34:1069–1075. 2009.PubMed/NCBI
24	Kaur S, Lotsari JE, Al-Sohaily S, Warusavitarne J, Kohonen-Corish MR and Peltomäki P: Identification of subgroup-specific miRNA patterns by epigenetic profiling of sporadic and Lynch syndrome-associated colorectal and endometrial carcinoma. Clin Epigenetics. 7:202015. View Article : Google Scholar : PubMed/NCBI
25	Wang Y, Fu J, Jiang M, Zhang X, Cheng L, Xu X, Fan Z, Zhang J, Ye Q and Song H: MiR-410 is overexpressed in liver and colorectal tumors and enhances tumor cell growth by silencing FHL1 via a direct/indirect mechanism. PLoS One. 9:e1087082014. View Article : Google Scholar : PubMed/NCBI
26	Slattery ML, Wolff E, Hoffman MD, Pellatt DF, Milash B and Wolff RK: MicroRNAs and colon and rectal cancer: Differential expression by tumor location and subtype. Genes Chromosomes Cancer. 50:196–206. 2011. View Article : Google Scholar : PubMed/NCBI
27	Peterson SM, Thompson JA, Ufkin ML, Sathyanarayana P, Liaw L and Congdon CB: Common features of microRNA target prediction tools. Front Genet. 5:232014. View Article : Google Scholar : PubMed/NCBI
28	Vlachos IS and Hatzigeorgiou AG: Online resources for miRNA analysis. Clin Biochem. 46:879–900. 2013. View Article : Google Scholar : PubMed/NCBI
29	Fernandes MS, Carneiro F, Oliveira C and Seruca R: Colorectal cancer and RASSF family - a special emphasis on RASSF1A. Int J Cancer. 132:251–258. 2013. View Article : Google Scholar
30	Richter AM, Pfeifer GP and Dammann RH: The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta. 1796:114–128. 2009.PubMed/NCBI
31	Volodko N, Gordon M, Salla M, Ghazaleh HA and Baksh S: RASSF tumor suppressor gene family: Biological functions and regulation. FEBS Lett. 588:2671–2684. 2014. View Article : Google Scholar : PubMed/NCBI